Trial Search Results
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Stanford is currently not accepting patients for this trial.
- Biological: sipuleucel-T
- subjects must be at least 18 years of age
- subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to
- subjects must understand and sign an informed consent form
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study